Skip to main content
. 2019 Mar 18;8(3):380. doi: 10.3390/jcm8030380

Figure 5.

Figure 5

Evaluation of IL10+cells at T0 and after III and VI cycles of treatment in bevacizumab patients and fold increase of the percentage of IL10+cells after III and VI cycles of therapy compared with T0 (%IL10 III or %IL10 VI/%IL10 T0) in R and N-R patients belonging to the Bev group.